QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis

QiangGuYin (QGY) is a common Traditional Chinese medicine prescription for the treatment of osteoporosis. Previous clinical studies have found that QGY effectively improves bone mineral density (BMD) in postmenopausal women, but its underlying mechanism remains unclear. The osteoprotegerin (OPG)/rec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuefei Li, Longkang Cui, Wenhua Chen, Yuan Fang, Gaobo Shen, Zhen Li, Bingbing Zhang, Lianguo Wu
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Other systems of medicine RZ201-999
Acceso en línea:	https://doaj.org/article/0c114a42fbf04e1ca074e689a5dda35e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c114a42fbf04e1ca074e689a5dda35e
record_format	dspace
spelling	oai:doaj.org-article:0c114a42fbf04e1ca074e689a5dda35e2021-11-08T02:36:06ZQiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis1741-428810.1155/2021/7114139https://doaj.org/article/0c114a42fbf04e1ca074e689a5dda35e2021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/7114139https://doaj.org/toc/1741-4288QiangGuYin (QGY) is a common Traditional Chinese medicine prescription for the treatment of osteoporosis. Previous clinical studies have found that QGY effectively improves bone mineral density (BMD) in postmenopausal women, but its underlying mechanism remains unclear. The osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL)/receptor activator of nuclear factor kappa B (RANK) pathway is a classic pathway involved in osteoporosis. Secretin levels are a serum marker of osteoporosis, but their effect on the OPG/RANKL/RANK pathway has not been reported. Hence, we investigated the relationship between the OPG/RANKL/RANK pathway and secretin and further revealed the mechanism underlying the effect of QGY in the treatment of osteoporosis. Mice were divided into secretin knockdown, secretin overexpression, and corresponding control groups. Micro-computed tomography was used to detect BMD in different groups, and the results show that QGY significantly improved BMD in mice of the secretin knockdown group. To further verify this, the serum levels of OPG, RANKL, RANK, and secretin were measured by enzyme-linked immunosorbent assays, and femur levels of OPG, RANKL, RANK, and secretin were evaluated by real-time quantitative PCR and western blotting. The results show that the expression of OPG was inhibited and that of RANKL and RANK was increased in mice from the secretin knockdown group, whereas the expression of OPG was upregulated and that of RANKL and RANK was downregulated after QGY intervention. Therefore, QGY inhibited bone resorption by promoting the expression of secretin and modulating the OPG/RANKL/RANK pathway. In addition to the effect of QGY, we also revealed the general regulatory effect of secretin on the OPG/RANKL/RANK pathway. We conclude that QGY modulates the OPG/RANKL/RANK pathway by increasing secretin levels during treatment of primary type I osteoporosis. This work provides a theoretical basis for the clinical use of QGY in the treatment of osteoporosis.Xuefei LiLongkang CuiWenhua ChenYuan FangGaobo ShenZhen LiBingbing ZhangLianguo WuHindawi LimitedarticleOther systems of medicineRZ201-999ENEvidence-Based Complementary and Alternative Medicine, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Other systems of medicine RZ201-999
spellingShingle	Other systems of medicine RZ201-999 Xuefei Li Longkang Cui Wenhua Chen Yuan Fang Gaobo Shen Zhen Li Bingbing Zhang Lianguo Wu QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis
description	QiangGuYin (QGY) is a common Traditional Chinese medicine prescription for the treatment of osteoporosis. Previous clinical studies have found that QGY effectively improves bone mineral density (BMD) in postmenopausal women, but its underlying mechanism remains unclear. The osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL)/receptor activator of nuclear factor kappa B (RANK) pathway is a classic pathway involved in osteoporosis. Secretin levels are a serum marker of osteoporosis, but their effect on the OPG/RANKL/RANK pathway has not been reported. Hence, we investigated the relationship between the OPG/RANKL/RANK pathway and secretin and further revealed the mechanism underlying the effect of QGY in the treatment of osteoporosis. Mice were divided into secretin knockdown, secretin overexpression, and corresponding control groups. Micro-computed tomography was used to detect BMD in different groups, and the results show that QGY significantly improved BMD in mice of the secretin knockdown group. To further verify this, the serum levels of OPG, RANKL, RANK, and secretin were measured by enzyme-linked immunosorbent assays, and femur levels of OPG, RANKL, RANK, and secretin were evaluated by real-time quantitative PCR and western blotting. The results show that the expression of OPG was inhibited and that of RANKL and RANK was increased in mice from the secretin knockdown group, whereas the expression of OPG was upregulated and that of RANKL and RANK was downregulated after QGY intervention. Therefore, QGY inhibited bone resorption by promoting the expression of secretin and modulating the OPG/RANKL/RANK pathway. In addition to the effect of QGY, we also revealed the general regulatory effect of secretin on the OPG/RANKL/RANK pathway. We conclude that QGY modulates the OPG/RANKL/RANK pathway by increasing secretin levels during treatment of primary type I osteoporosis. This work provides a theoretical basis for the clinical use of QGY in the treatment of osteoporosis.
format	article
author	Xuefei Li Longkang Cui Wenhua Chen Yuan Fang Gaobo Shen Zhen Li Bingbing Zhang Lianguo Wu
author_facet	Xuefei Li Longkang Cui Wenhua Chen Yuan Fang Gaobo Shen Zhen Li Bingbing Zhang Lianguo Wu
author_sort	Xuefei Li
title	QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis
title_short	QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis
title_full	QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis
title_fullStr	QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis
title_full_unstemmed	QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis
title_sort	qiangguyin modulates the opg/rankl/rank pathway by increasing secretin levels during treatment of primary type i osteoporosis
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/0c114a42fbf04e1ca074e689a5dda35e
work_keys_str_mv	AT xuefeili qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis AT longkangcui qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis AT wenhuachen qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis AT yuanfang qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis AT gaoboshen qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis AT zhenli qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis AT bingbingzhang qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis AT lianguowu qiangguyinmodulatestheopgranklrankpathwaybyincreasingsecretinlevelsduringtreatmentofprimarytypeiosteoporosis
_version_	1718443160769658880

QiangGuYin Modulates the OPG/RANKL/RANK Pathway by Increasing Secretin Levels during Treatment of Primary Type I Osteoporosis

Ejemplares similares